Physician profile
John G Dodd
NPI 1215190400
$6,469.79
in general payments reported to CMS, 2019-2025
21 companies · $795 in 2025
The $795 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $411 · 2021: $1,706 · 2022: $908 · 2023: $1,095 · 2024: $1,035 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,899.98 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,286.44 | 2020-2025 | Clareon, Argos, Acrysof Iq Panoptix Uv Iol |
| Biotissue Holdings INC. | $1,573.37 | 2019-2022 | |
| Abbvie INC. | $676.69 | 2022-2025 | Durysta, Vuity |
| Johnson & Johnson Surgical Vision, INC. | $542.84 | 2019-2022 | |
| Rxsight INC | $246.94 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $228.53 | 2019-2023 | Cequa |
| Ivantis, INC | $195.38 | 2019-2021 | |
| Amgen INC. | $170.44 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $149.69 | 2024 | Xdemvy |
| Allergan, INC. | $108.94 | 2020-2022 | |
| Horizon Therapeutics Plc | $49.69 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.34 | 2019 | |
| Sight Sciences, INC. | $37.44 | 2021-2022 | |
| Astellas Pharma US INC | $27.00 | 2025 | Izervay |
| Glaukos Corporation | $26.75 | 2025 | Idosetr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $24.04 | 2020 | |
| Thea Pharma INC. | $19.54 | 2024 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $16.43 | 2019 | |
| Bausch & Lomb Americas INC. | $14.57 | 2025 | Envista Envy Iol |
| Lombart Brothers, INC. | $14.38 | 2019 | |
| New World Medical,INC. | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.